Dr Michael Bowdish is principal investigator for our trial at USC. He is listed person on clinicaltrials.gov for only one other trial (which isn’t a COVID19 one). The trial he is talking about has target of 300 participants (he says 30 is 10%), has NIH involvement and is treating critical COVID19 patients (note first participant he talks about died in days). That is just too much to believe it is just coincidence. Also, the blog post was edited just hours after it started being discussed here.
As for it being 30 total, rather than 30 just at USC, the earlier article linked previously in this thread said they had enrolled over 20 at USC. So, I think it is clear there are 30 at USC.
Dr Michael Bowdish is principal investigator for our trial at...
-
- There are more pages in this discussion • 28 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
-0.025(2.17%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.16 | $1.11 | $7.363M | 6.488M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 94863 | $1.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 5000 | 2 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |